Navigation Links
FDA Panel Backs Tougher Warning on Asthma Drugs for Kids
Date:11/28/2007

Serevent and Advair need specific child warnings on side effects, pediatric panel says; action follows panel's recommendation to toughen label on flu drugs for kids.

TUESDAY, Nov. 27 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel on Wednesday urged that stronger label warnings focused on children be added to the packaging for Serevent and Advair, two widely used asthma drugs.

Both drugs are long-acting beta agonist medications containing salmeterol, and are used as asthma prevention in children and adults age 4 and up.

But last year -- after a 2005 panel investigation focused mainly on the drugs' use by adults -- the FDA added a strong "black box" warning on both medications that they "may increase the risk of asthma-related death."

The panel's new recommendation is that this warning be extended specifically to pediatric users of the two drugs, according to Marketwatch, and that it include mention of the fact that the drugs could boost the risk of asthma-linked hospitalizations.

Both drugs are made by GlaxoSmithKline, which said it believed the current black-box warning was sufficient, according to Marketwatch. The FDA says it also plans a new safety review of the two drugs.

The announcement came after the same panel, the FDA's Pediatric Advisory Committee, recommended on Tuesday that the prescription flu drug Tamiflu (oseltamivir) should have a stronger warning label to reflect reports of bizarre behaviors and deaths among children who use the medication.

On Wednesday, the drug's manufacturer, Roche, accepted the recommendation, the Associated Press reported.

The panel, in a 9-5 vote, said Roche should change the drug's prescribing information because it doesn't adequately explain side effects reported by hundreds of patients in Japan and the United States, according to Bloomberg News.

The drug's label mentions reports of delirium and self-injury, primarily among children in Japan, but the advisory panel said the language should state that several patients died as a result of these behaviors, AP reported.

A spokeswoman for Roche said Wednesday that all flu patients, not just those taking Tamiflu, should be warned that the illness posed a risk of psychiatric problems. She stressed there was no causal relationship between Tamiflu and the reported cases of delirium and hallucinations, AP reported.

In addition, the FDA panel recommended that labeling for the flu drug Relenza, (zanamivir), should also reflect reports of abnormal behavior, according to Bloomberg.

The FDA is not obliged to follow its expert panels' recommendation, but it usually does. A safety review released Friday by the FDA's Division of Antiviral Products urged stronger label warnings for both flu drugs, including stricter monitoring of children taking these drugs.

According to the FDA safety review, there have been 596 reported cases of psychiatric behavior associated with Tamiflu use. Most of these cases happened among patients aged 21 or younger. The majority (75 percent) occurred in Japan.

Fifty-nine of the cases were classified as delirium with impulsive behavior and self-injury. Delirium, delusions, hallucinations or psychosis accounted for another 225 cases. In total, five children died "as a result of falls from windows or balconies or running into traffic," the safety review found, and three adults committed suicide. So far, there haven't been any such cases reported in the United States, according to the FDA.

The FDA safety review also reported that in cases involving Relenza, mostly in Japan, there have been 115 reports of "delirium with impulsive behavior and self-injury in which the patient expressed 'fear' and attempted to flee or expressed a desire to 'jump,'" the agency said. There were no deaths associated with Relenza.

During its meeting on Tuesday, the advisory panel said it was unclear whether the psychiatric problems are a side effect of Tamiflu or the flu itself, AP reported.

At the hearing, representatives of Roche told the panelists that the flu itself, not Tamiflu, caused the bizarre behaviors.

"We feel that the current U.S. prescribing information is an accurate assessment of the current data," Jonathan Solsky, Roche's director of drug safety risk management, testified, according to Bloomberg.

In a statement released after the meeting, Roche reiterated its faith in the drug. "According to data analyzed from two U.S. claims databases of more than 150,000 patients, there is no increased risk for neuropsychiatric events in influenza patients treated with Tamiflu compared to untreated influenza patients," the statement said.

GlaxoSmithKline, the maker of Relenza, also released a statement after the meeting. "GSK was pleased to have the opportunity to present safety information on Relenza to the Pediatric Advisory Committee showing no conclusive evidence of a causal association between Relenza and neuropsychiatric events," the statement said.

"We believe the current Relenza U.S. prescribing information accurately reflects the safety profile of the drug," the company added.

The FDA first began reviewing Tamiflu in 2005. Since November 2006, the drug's label has had a warning focused on self-injury and delirium, advising that patients be monitored during treatment. In March, the Japanese Ministry of Health, Labor and Welfare limited Tamiflu use in patients aged 10 to 19 years old.

Tamiflu is approved both as a preventative and a treatment for flu for adults and children aged 1 year and older.

Relenza is approved as both a flu preventative and a treatment in adults and children aged 5 years old and older.

More information

For more on the flu, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Pediatric Safety Update for Tamiflu, Division of Antiviral Products, U.S. Food and Drug Administration; Nov. 27, 2007, statements, GlaxoSmithKline and Roche; Bloomberg news; Associated Press, MarketWatch


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Backs Tougher Warning  on Asthma Drugs for Kids
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to visit ... Butler products. Ken was impressed with the safety and reliability of the Stannah ... on his show. This endorsement by Ken Matthews can be heard on News ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data ... has introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. ... EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... 17, 2017 Research and Markets has announced the ... to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:2/17/2017)... 17, 2017 Arvinas LLC, a private biotechnology ... protein degradation, today announced the presentation of new preclinical ... a poster session at the American Society of Clinical ... Orlando, FL. "The ... and the potential of PROTACs to drive durable and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
Breaking Medicine Technology: